REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Hair Growth Stack

Skin & Hairintermediate

78

synergy

78
Share
Peptides

3

Avg Daily mcg

3,250

Level

intermediate

Added

May 17, 2026

Overview

The Hair Growth Stack combines three regenerative peptides that target different aspects of hair follicle biology to promote hair density, thickness, and growth cycle optimization. GHK-Cu is the primary driver of this stack''s hair-specific effects. The copper-binding tripeptide has been shown to increase hair follicle size, stimulate proliferation of follicular keratinocytes, and extend the anagen (active growth) phase of the hair cycle. Studies demonstrate that GHK-Cu promotes expression of growth factors specific to the dermal papilla cells that control hair follicle activity, including FGF-7, VEGF, and Wnt signaling pathway components. Topical application allows direct delivery to the scalp, though subcutaneous injection provides systemic support for body-wide follicle health. BPC-157 contributes to hair restoration through its angiogenic properties — hair follicles are among the most metabolically active structures in the body and require robust blood supply. In androgenetic alopecia, miniaturization of follicles correlates with reduced perifollicular vascularity. BPC-157''s promotion of new blood vessel formation around follicles restores the nutrient and oxygen delivery needed for full-size hair production. Additionally, its anti-inflammatory effects may help resolve the chronic perifollicular inflammation (micro-inflammation) now recognized as a contributor to pattern hair loss. TB-500 provides systemic tissue remodeling support through its actin-polymerization and cell migration effects. Hair follicle cycling involves extensive tissue remodeling — the follicle partially destructs during catagen, then regenerates from stem cells during the telogen-to-anagen transition. TB-500''s promotion of stem cell migration and tissue repair supports these regenerative processes. The three-peptide combination addresses follicular vascularity (BPC-157), direct follicle stimulation and matrix remodeling (GHK-Cu), and systemic tissue repair capacity (TB-500). Results typically require 3-6 months of consistent use, as hair growth cycles operate on timescales of months rather than weeks.

Dosing Protocol

GHK-Cu

Every day· topical/subcutaneous

Read more about GHK-Cu →

500 mcg

per dose

BPC-157

Every day· subcutaneous

Read more about BPC-157 →

250 mcg

per dose

TB-500

2x/week· subcutaneous

Read more about TB-500 →

2,500 mcg

per dose

Goals & Evidence

Hair growthFollicle stimulationHair densityScalp vascularityAlopecia support
Evidence tier:Animal Studies

Warnings

  • Hair-related applications of BPC-157 and TB-500 are off-label. GHK-Cu topical data is strongest for this indication.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.